Laboratory Corporation of America Holdings (LabCorp) LH had a significant presence in the news with notable mentions on company's performance, future strategy, market predictions and acquisitions. LabCorp
outperformed its competitors on several occasions, despite some daily losses. Investors holding stock for the previous
five years have seen an increase of
67%. The company's
Q4 earnings surpassed estimates, even as they reported a mixture of Q4 and full year 2023 results.
LabCorp announced a live stream of its annual shareholder meeting and a Confirmatory Acquisition of Select
Invitae assets which was approved by US Bankruptcy Court. In addition, Labcorp secured a win in a bid to acquire select assets of
BioReference Health's Diagnostics Business. Further anticipated growth is signaled by strong Q1 earnings estimates, raising the 2024 EPS view. Despite this, some asset management companies including
Swiss National Bank and
Russell Investments Group Ltd. reduced their holdings in the company. The company's
Quarterly Dividend was announced and highlighted a pay-out of $0.72.
Partnerships were announced including Geneoscopy which won FDA approval for a colorectal cancer test and a collaboration with Hawthorne Effect. Interesting developments include the expansion of LabCorp's strategic alliances despite falling test sales and the introduction of a weight loss management portfolio.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Wed, 08 May 2024 15:11:52 GMT -
Rating 6
- Innovation 3
- Information 7
- Rumor -2
